A randomized, double-blind trial to compare shock wave frequencies of 60 and 120 shocks per minute for upper ureteral stones
J Urol · 2009 · Vol. 182 · Issue 4 · 1418-1423
Academy Summary
A randomized, double-blind trial to compare shock wave frequencies of 60 and 120 shocks per minute for upper ureteral stones examined a clinically important component of shock wave lithotripsy, with particular relevance to SWL Treatment Optimisation.
The investigators used a Randomized Double-Blind Trial in adults with upper ureteral stones. This design strengthens comparison between the treatment strategies studied, although the conclusions still remain tied to the lithotripter, protocol and eligibility criteria used.
For proximal ureteral stones, 60 shocks/min achieved better reported stone-free outcome and reduced auxiliary treatment compared with 120 shocks/min, although treatment took longer.
Shock-wave rate changes the effectiveness of each shock, not only the duration of the procedure.
The rate literature is central to modern SWL optimisation because it demonstrates that treatment speed and treatment efficiency are not synonymous. Slower delivery can allow cavitation bubbles to dissipate and may improve fragmentation efficiency, although the optimal rate must balance efficacy and treatment time.
Published in 2009, the study predates several contemporary refinements in SWL technique. The clinical principle remains relevant, but absolute rates and machine settings should be interpreted in their technological era.
For the Lithotripsy Academy database, the paper is most useful when interpreted as part of the complete treatment pathway rather than as an isolated numerical rule. Patient selection determines the opportunity for success, while targeting, coupling, shock-wave rate, energy strategy and operator technique determine how effectively that opportunity is converted into fragmentation and clearance.
Comments & Discussion0 comments
Discuss the publication's evidence, limitations and practical relevance. Please do not include identifiable patient information or individual medical advice.
No comments yet. Start the discussion.
Please log in to join the discussion.
